HOME >> MEDICINE >> NEWS
AMPAKINE compounds a new potential treatment for respiratory depression

was intended.

The drug tested in this study belongs to a novel class of molecules known as AMPAKINE compounds being developed by Cortex Pharmaceuticals, Inc. located in Irvine, California. AMPAKINE compounds act on the most common excitatory receptor in the brain, the AMPA "Glutamate type receptor," which has been shown in rodent models to boost the brain's own protein for improving age-related deficits in memory mechanisms. In primate models AMPAKINE compounds have replicated the studies in rodents and in adults patients suffering from Attention Deficit Hyperactivity Disorder, significant clinical and statistical improvement in increase attention and decrease hyperactivity have been observed. The U. Alberta research provide evidence that another important AMPAKINE indication is to stimulate primitive areas of the brain called the pre-Botzinger Complex responsible for breathing, without causing side effects. The pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties that have been identified in this brain region.

In a study published in 2006, Dr. John J. Greer of U. Alberta demonstrated that certain AMPAKINE compounds enhance the respiratory drive and breathing rhythm at the brain-stem level containing the pre-Botzinger Complex in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants.

Dr. Greer found that respiratory depression induced by these agents can be reversed or prevented in test animals with an experimental AMPAKINE drug, without a reduction of pain relief or sedation.

Greer and coworkers treated rats with the opioids analgesic fentanyl or the barbiturate sedative Phenobarbital, both commonly prescribed in the United States. Greer used a technique known as plethysmography, which measures blood flow throughout
'"/>

Contact: Mark Varney
mvarney@cortexpharm.com
949-231-0672
Cortex Pharmaceuticals
4-Jun-2007


Page: 1 2 3 4 5

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
3. U of M researchers discover compounds to shrink tumors
4. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue
5. New compounds fight chronic symptoms of bowel disorders
6. New synthetic compounds appear to prevent brain cell death
7. Phenolic compounds may explain Mediterranean diet benefits
8. Vitamin D compounds show promise for prevention of prostate cancer
9. Hebrew University researcher develops compounds to control bacteria
10. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
11. Electric fields have potential as a cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... TX (PRWEB) , ... February 24, 2017 , ... ... offering promotions on tooth replacement options at his office, Antoine Dental Center. Currently, ... implants for $18,499. Some restrictions may apply, but patients can learn more about ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... of Liberty University, has officially announced the appointment of Peter A. Bell, DO, ... of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney ... Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. ... to Highway 121. , As the practice has grown, the need for more space ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... present generation. Yisrayl makes an astounding statement when he says that the entire ... the Bible details the current times so plainly that anyone should be able to ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology:
Cached News: